Our findings suggested that genetically predicted SGLT2 inhibition played a causal role in reducing the risk of several malignancies, including oropharyngeal cancer, bronchial and lung cancer, rectal cancer, ovarian cancer, non-melanoma skin cancer, and multiple myeloma. Here, SLC5A2 is linked to ovarian carcinoma.